21900-34-5

Upstream product

• 42860-10-6 3-bromo-4-chlorobenzoic acid 
• 89-62-3 4-methyl-2-nitroaniline 
• 57310-39-1 2-bromo-1-chloro-4-methylbenzene 
• 2840-28-0 3-amino-4-chloro-benzoic acid 

Downstream Products

• 57487-46-4 C₂₂H₁₅BrCl₃N₅O 
• 913067-93-3 3-bromo-4-chloro-N-(3-(trifluoromethyl)phenyl)benzamide 
• 791137-22-9 3-bromo-4-chlorobenzamide 
• 938163-32-7 C₉H₅BrClNO 
• 834895-52-2 3-bromo-4-pyrrolidinobenzophenone 
• 834895-57-7 1-(3-bromo-4-pyrrolidinophenyl)-1-phenylprop-2-yn-1-ol 
• 834895-43-1 3-(3-bromo-4-pyrrolidinophenyl)-3-phenyl-3H-naphtho[2,1-b]pyran 
• 1025772-28-4 (R)-3-bromo-4-chloro-N-(1-phenylethyl)benzamide 
• 1070892-06-6 3-bromo-4-chloro-N-(2-methoxy-phenyl)-benzamide 
• 1070892-12-4 3-bromo-4-chloro-N-(2-hydroxy-phenyl)-N-methyl-benzamide 
• 1070892-27-1 3-bromo-4-chloro-N-(2-hydroxy-6-methyl-phenyl)-benzamide 
• 1070892-36-2 4-[2-(3-bromo-4-chloro-benzoylamino)-phenyl]-butyric acid methyl ester 
• 1207192-77-5 C₁₅H₁₁BrClF₃N₂O₃S 
• 1070892-07-7 3-bromo-4-chloro-N-(2-methoxy-phenyl)-N-methyl-benzamide 

Relevant academic research and scientific papers

BENZAZOLE DERIVATIVE HAVING HETEROARYL GROUP AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME

Disclosed is a benzazole derivative having a heteroaryl group, wherein the benzazole derivative having the heteroaryl group is represented by Chemical Formula 1. Also disclosed is an organic electroluminescence device including an organic layer containing

Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi

Chagas disease is a neglected parasitic disease caused by the parasitic protozoan Trypanosoma cruzi and currently affects around 8 million people. Previously, 2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0227) was discovered to be a sub-micromolar inhibitor (pIC50=6.4) of T. cruzi. So far, SAR investigations of this scaffold have focused on the alkoxy substituent, the pyrazolone nitrogen substituent and the aromatic substituent of the core phenylpyrazolone. In this study, modifications of the phenyldihydropyrazolone scaffold are described. Variations were introduced by installing different substituents on the phenyl core, modifying the geminal dimethyl and installing various bio-isosteres of the dihydropyrazolone group. The anti T. cruzi activity of NPD-0227 could not be surpassed as the most potent compounds show pIC50 values of around 6.3. However, valuable additional SAR data for this interesting scaffold was obtained, and the data suggest that a scaffold hop is feasible as the pyrazolone moiety can be replaced by a oxazole or oxadiazole with minimal loss of activity.

COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2/su

Calcium receptor modulating agents

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants

We used molecular modeling to design de novo broad-range inhibitors against wild type and drug-resistant variants of the reverse transcriptase (RT) of human immunodeficiency virus type-1 (HIV-1). First, we screened for small fragments that would interact with each one of four RT structures (one wild type and three mutants). Then, these fragments were linked to build a scaffold molecule. Out of 27 different compounds that were synthesized, four inhibited the DNA polymerase activity of RT with IC50 values below 10 μM. Compound 5f inhibited RT with an IC50 value of about 3.5 μM, while inhibiting drug-resistant RT variants more efficiently than the clinically used drug, nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b: 2′,3′-e-]-[1,4]diazepin-6-one). 5f also inhibited the RT ribonuclease H activity with an IC50 of 20 μM and therefore, unlike nevirapine, targets both RT activities. Accordingly, 5f can serve as lead for developing novel inhibitors against RT that may be used to suppress HIV-1 growth.